Last reviewed · How we verify
Diagnostic performances of biomarkers combination
Diagnostic performances of biomarkers combination is a Biologic drug developed by Hospices Civils de Lyon. It is currently in Phase 1 development.
At a glance
| Generic name | Diagnostic performances of biomarkers combination |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diagnostic performances of biomarkers combination CI brief — competitive landscape report
- Diagnostic performances of biomarkers combination updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI
Frequently asked questions about Diagnostic performances of biomarkers combination
What is Diagnostic performances of biomarkers combination?
Diagnostic performances of biomarkers combination is a Biologic drug developed by Hospices Civils de Lyon.
Who makes Diagnostic performances of biomarkers combination?
Diagnostic performances of biomarkers combination is developed by Hospices Civils de Lyon (see full Hospices Civils de Lyon pipeline at /company/hospices-civils-de-lyon).
What development phase is Diagnostic performances of biomarkers combination in?
Diagnostic performances of biomarkers combination is in Phase 1.